Premastectomy Radiotherapy Followed by Immediate Breast Reconstruction Demonstrates Safety
By Lori Solomon HealthDay Reporter
WEDNESDAY, April 10, 2024 -- Premastectomy radiotherapy (PreMRT) and regional node irradiation (RNI) followed by immediate breast reconstruction (IMBR) is feasible and safe, according to a study published online April 5 in JAMA Network Open.
Mark V. Schaverien, M.D., from University of Texas MD Anderson Cancer Center in Houston, and colleagues assessed the feasibility and safety of PreMRT followed by mastectomy and IMBR in 49 patients with cT0-T3, N0-N3b breast cancer.
The researchers reported that 48 patients underwent mastectomy with IMBR at a median of 23 days after radiotherapy. Techniques included microvascular autologous flap reconstruction (41), latissimus dorsi pedicled flap reconstruction (five), and tissue expander placement (two). No complete autologous flap losses were recorded and one patient underwent tissue expander explantation. In total, eight patients (17 percent) had mastectomy skin flap necrosis of the treated breast, with one patient undergoing reoperation. There were no locoregional recurrences or distant metastasis during a median 29.7 months of follow-up.
"Our trial represents a pioneering achievement in the United States, demonstrating the safety and effectiveness of this paradigm-shifting treatment sequence for patients with breast cancer," Schaverien said in a statement. "This sequence not only enhances surgical outcomes but also eliminates the need for patients to defer breast reconstruction surgery, significantly enhancing their quality of life."
Several authors disclosed ties to industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Perioperative Chemo Improves Progression-Free Survival in Pancreatic Cancer
TUESDAY, July 2, 2024 -- For patients with resectable pancreatic ductal adenocarcinoma (PDAC), the 12-month progression-free survival (PFS) may be increased with neoadjuvant...
Few Patients With Positive Margins After Basal Cell Excision Have Recurrence
MONDAY, July 1, 2024 -- Among patients with incompletely excised basal cell carcinoma (BCC), only about 16 percent with positive histopathologic margins have clinical recurrence...
NCCN: Cancer Drug Shortages Remain a Challenge for Clinicians
FRIDAY, June 28, 2024 -- Almost 90 percent of medical centers report cancer drug shortages, which often impact clinical trials, according to the results of a National...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.